Transcription of molnupiravir COVID19-MSD - Assessment Report Rev. 1
{{id}} {{{paragraph}}}
Official address Domenico Scarlattilaan 6 1083 HS Amsterdam The Netherlands An agency of the European Un on Address for visits and deliveries Refer to Send us a question Go to Telephone +31 (0)88 781 6000 European Medicines Agency, 2022. Reproduction is authorised provided the source is acknowledged. 27 January 2022 EMA/719664/2021 Rev. 11 Committee for Medicinal Products for human Use (CHMP) Assessment Report Procedure under Article 5(3) of Regulation (EC) No 726/2004 Use of molnupiravir for the treatment of COVID-19 INN: molnupiravir Procedure number: EMEA/H/A-5 (3)/1512 Note: Assessment Report as adopted by the CHMP with all information of a commercially confidential nature deleted. 1 Statement on BCS classification was updated Assessment Report EMA/719664/2021 Page 2/90 Table of contents Table of contents.
Committee for Medicinal Products for Human Use (CHMP) Assessment report . Procedure under Article 5(3) of Regulation EC) No 726/2004( Use of molnupiravir for the treatment of COVID-19 . INN: molnupiravir . Procedure number: EMEA/H/A-5(3)/1512 . Note: Assessment report as adopted by the CHMP with all information of a
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document:
{{id}} {{{paragraph}}}